| (210) | Number of the EPO application | 18731845 |
| (220) | Filing date of the EPO application | 2018.06.21 |
| (80) | EPO patent specification publication (B) | EPB nr. 49/2023, 2023.12.06 |
| (110) | EPO patent number | 3641775 |
| (21) | Number of the application | e 2020 0463 |
| (71) | Name(s) of applicant(s), code of the country | LES LABORATOIRES SERVIER, FR;
NOVARTIS AG, CH; |
| (72) | Name(s) of inventor(s), code of the country | WEI Andrew, AU;
MOUJALLED Donia, AU;
POMILIO Giovanna, AU;
GENESTE Olivier, FR;
MARAGNO Ana-Leticia, FR; |
| (73) | Name(s) of owner(s), code of the country | LES LABORATOIRES SERVIER, FR;
NOVARTIS AG, CH; |
| (54) | Title of the invention | COMBINATION OF A MCL-1 INHIBITOR AND A STANDARD OF CARE TREATMENT FOR HEMATOLOGIC CANCERS, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | A61K 31/519 (2006.01.01); A61K 31/5377 (2006.01.01); A61K 31/55 (2006.01.01); A61P 35/00 (2006.01.01); A61K 45/06 (2006.01.01) |
| (19) | Country | FR |
| (41) | Date of publication of the application | 2020.05.31 |
| (30) | Priority | 201762523389 P, 2017.06.22, US; 17189550, 2017.09.06, EP |
| (86) | International application | PCT/EP2018/066551, 2018.06.21 |
| (87) | International publication | WO 2018/234433, 2018.12.27 |